3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Melanoma
2
Colorectal Neoplasms
2
Advanced Solid Tumors
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Unspecified, Adult
1
Prostatic Neoplasms, Castration-Resistant
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
Interventions
Dexamethasone
363
Bortezomib
232
Lenalidomide
202
Cyclophosphamide
174
Melphalan
154
Calcium Dobesilate
107
Peripheral Blood Stem Cell Transplantation
92
fludarabine phosphate
84
Thalidomide
81
Filgrastim
71
carfilzomib
68
pomalidomide
66
Granulocyte Colony-Stimulating Factor
60
Mycophenolic Acid
59
Busulfan
57
daratumumab
55
Whole-Body Irradiation
54
Tacrolimus
51
ixazomib
50
Prednisone
50
Cyclosporine
49
fludarabine
46
Antilymphocyte Serum
35
Etoposide
30
dexamethasone acetate
29
Methotrexate
29
plerixafor
27
Radiotherapy
26
Doxorubicin
26
dexamethasone 21-phosphate
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Multiple Myeloma
×
zimberelimab
×
Clear all
NCT04772989
2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1
Completed
94 enrolled